Stockscreener 앱 받기
3.16
3.27%
0.10
시간 외 거래:
3.24
0.08
+2.53%
Bioline Rx Ltd Adr 주식(BLRX)의 최신 뉴스
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls - TipRanks
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Barchart.com
BLRX Technical Analysis | Trend, Signals & Chart Patterns | BIOLINERX LTD-SPONS ADR (NASDAQ:BLRX) - ChartMill
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Barchart.com
BLRX Stock Price, Quote & Chart | BIOLINERX LTD-SPONS ADR (NASDAQ:BLRX) - ChartMill
BioLineRx and Hemispherian Report Strong Preclinical GLIX1 Data in Temozolomide-Resistant Glioblastoma - TipRanks
BioLineRx reports preclinical data for GBM treatment GLIX1 - Investing.com
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - Barchart.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Number of shareholders of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial - TipRanks
BioLineRx doses first patient in glioblastoma drug trial By Investing.com - Investing.com South Africa
BioLineRx doses first patient in glioblastoma drug trial - Investing.com
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Barchart.com
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT) - The Globe and Mail
BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target - TipRanks
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
Operating cash flow per share of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx launches trial of brain cancer drug GLIX1 By Investing.com - Investing.com South Africa
BioLineRx initiates Phase 1/2a study of GLIX1 - tipranks.com
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Finviz
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma - TipRanks
BioLineRx launches trial of brain cancer drug GLIX1 - investing.com
BioLineRx provides corporate update - tipranks.com
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q4 2025 sees revenue drop, stock dips - Investing.com
BioLineRx Reports 2025 Financial Results and Provides Corporate Update - Finviz
BioLineRx Sets March Start for GLIX1 Brain Cancer Trial as 2025 Results Show Leaner R&D-Focused Model - TipRanks
Going concern and debt pressures at BioLineRx (NASDAQ: BLRX) - Stock Titan
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings - Sahm
BioLineRx to Report 2025 Annual Results on March 23, 2026 - Finviz
BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute - TipRanks
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Beyond Air (XAIR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Icon (ICLR) and Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Radiopharm Theranostics Limited Sponsored ADR (RADX) and Resmed (RMD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA) - The Globe and Mail
BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges - MSN
BioLineRx Reports Q3 2025 Results and Strategic Expansion - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss By Investing.com - Investing.com South Africa
BioLineRx Announces Q3 2025 Financial Results and New Joint Venture - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss - Investing.com
BioLineRx shares rise over 7% on better-than-expected earnings By Investing.com - Investing.com Canada
BioLineRx shares rise over 7% on better-than-expected earnings - Investing.com
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Finviz
BioLine Rx's Earnings: A Preview - Sahm
BioLineRx stock rises after partner receives key patent allowance By Investing.com - Investing.com India
BioLineRx stock rises after partner receives key patent allowance - Investing.com
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - Finviz
0.98%
0.12%
자본화:
|
볼륨(24시간):